Patents by Inventor Reinhard Bolli

Reinhard Bolli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11723953
    Abstract: A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as ApoAI or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g/L and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75. The formulation is useful for treating diseases or conditions such as cardiovascular disease, hypercholesterolaemia and hypocholesterolaemia inclusive of acute coronary syndrome (ACS), atherosclerosis and myocardial infarction.
    Type: Grant
    Filed: July 6, 2021
    Date of Patent: August 15, 2023
    Assignee: CSL Limited
    Inventors: Samuel Wright, Martin Imboden, Reinhard Bolli, Marcel Waelchli
  • Publication number: 20220133852
    Abstract: A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as ApoAI or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g/L and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75. The formulation is useful for treating diseases or conditions such as cardiovascular disease, hypercholesterolaemia and hypocholesterolaemia inclusive of acute coronary syndrome (ACS), atherosclerosis and myocardial infarction.
    Type: Application
    Filed: July 6, 2021
    Publication date: May 5, 2022
    Applicant: CSL Limited
    Inventors: Samuel Wright, Martin Imboden, Reinhard Bolli, Marcel Waelchli
  • Patent number: 11058747
    Abstract: A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as ApoAI or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g/L and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75. The formulation is useful for treating diseases or conditions such as cardiovascular disease, hypercholesterolaemia and hypocholesterolaemia inclusive of acute coronary syndrome (ACS), atherosclerosis and myocardial infarction.
    Type: Grant
    Filed: June 19, 2019
    Date of Patent: July 13, 2021
    Assignee: CSL LIMITED
    Inventors: Samuel Wright, Martin Imboden, Reinhard Bolli, Marcel Waelchli
  • Publication number: 20200171126
    Abstract: A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as ApoAI or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g/L and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75. The formulation is useful for treating diseases or conditions such as cardiovascular disease, hypercholesterolaemia and hypocholesterolaemia inclusive of acute coronary syndrome (ACS), atherosclerosis and myocardial infarction.
    Type: Application
    Filed: June 19, 2019
    Publication date: June 4, 2020
    Applicant: CSL Limited
    Inventors: Samuel Wright, Martin Imboden, Reinhard Bolli, Marcel Waelchli
  • Patent number: 10335457
    Abstract: A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as ApoAI or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g/L and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75. The formulation is useful for treating diseases or conditions such as cardiovascular disease, hypercholesterolaemia and hypocholesterolaemia inclusive of acute coronary syndrome (ACS), atherosclerosis and myocardial infarction.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: July 2, 2019
    Assignee: CSL LIMITED
    Inventors: Samuel Wright, Martin Imboden, Reinhard Bolli, Marcel Waelchli
  • Publication number: 20170196935
    Abstract: A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as ApoAI or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g/L and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75. The formulation is useful for treating diseases or conditions such as cardiovascular disease, hypercholesterolaemia and hypocholesterolaemia inclusive of acute coronary syndrome (ACS), atherosclerosis and myocardial infarction.
    Type: Application
    Filed: August 19, 2016
    Publication date: July 13, 2017
    Inventors: Samuel Wright, Martin Imboden, Reinhard Bolli, Marcel Waelchli
  • Patent number: 9439946
    Abstract: A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as ApoAI or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g/L and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75. The formulation is useful for treating diseases or conditions such as cardiovascular disease, hypercholesterolaemia and hypocholesterolaemia inclusive of acute coronary syndrome (ACS), atherosclerosis and myocardial infarction.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: September 13, 2016
    Assignee: CSL LIMITED
    Inventors: Samuel Wright, Martin Imboden, Reinhard Bolli, Marcel Waelchli
  • Publication number: 20160022768
    Abstract: A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as ApoAI or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g/L and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75. The formulation is useful for treating diseases or conditions such as cardiovascular disease, hypercholesterolaemia and hypocholesterolaemia inclusive of acute coronary syndrome (ACS), atherosclerosis and myocardial infarction.
    Type: Application
    Filed: February 27, 2015
    Publication date: January 28, 2016
    Applicant: CSL Limited
    Inventors: Samuel Wright, Martin Imboden, Reinhard Bolli, Marcel Waelchli
  • Patent number: 8999920
    Abstract: A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as ApoAI or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g/L and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75. The formulation is useful for treating diseases or conditions such as cardiovascular disease, hypercholesterolaemia and hypocholesterolaemia inclusive of acute coronary syndrome (ACS), atherosclerosis and myocardial infarction.
    Type: Grant
    Filed: June 30, 2011
    Date of Patent: April 7, 2015
    Assignee: CSL Limited
    Inventors: Samuel Wright, Martin Imboden, Reinhard Bolli, Marcel Waelchli
  • Patent number: 8962802
    Abstract: This invention relates to protein separation and purification methods for both alpha-1-antitrypsin (AAT, also known as alpha-1 proteinase inhibitor, API, and A.sub.1-PI) and Apolipoprotein A-I (ApoA-1) from, for example, a fraction of human blood plasma. In certain embodiments, the invention provides methods for separating AAT from ApoA-1 at the initial stage of purification, so that the same starting material can be used as a source for both proteins. The methods further pertain to providing compositions of AAT and of ApoA-1 suitable for pharmaceutical use and are suitable for large-scale purification.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: February 24, 2015
    Assignee: CSL Behring GmbH
    Inventors: Nathan Brinkman, Douglas Bigler, Reinhard Bolli, Vreni Foertsch
  • Patent number: 8906368
    Abstract: The present invention relates to a protein preparation having increased stability, comprising a stabilizer selected from the group consisting of non-polar and basic amino acids and having a pH of 4.0 to 5.2. The invention further relates to a pharmaceutical composition and a method of stabilizing protein preparations.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: December 9, 2014
    Assignee: ZLB Behring AG
    Inventors: Reinhard Bolli, Gerhard Hodler, Regula Styger
  • Patent number: 8715652
    Abstract: The present invention relates to a protein preparation having increased stability, comprising a stabiliser selected from the group consisting of non-polar and basic amino acids and having a pH of 4.0 to 5.2. The invention further relates to a pharmaceutical composition and a method of stabilising protein preparations.
    Type: Grant
    Filed: November 17, 2004
    Date of Patent: May 6, 2014
    Assignee: CSL Behring AG
    Inventors: Reinhard Bolli, Gerhard Hodler, Regula Styger
  • Publication number: 20140094591
    Abstract: This invention relates to protein separation and purification methods for both alpha-1-antitrypsin (AAT, also known as alpha-1 proteinase inhibitor, API, and A.sub.1-PI) and Apolipoprotein A-I (ApoA-1) from, for example, a fraction of human blood plasma. In certain embodiments, the invention provides methods for separating AAT from ApoA-1 at the initial stage of purification, so that the same starting material can be used as a source for both proteins. The methods further pertain to providing compositions of AAT and of ApoA-1 suitable for pharmaceutical use and are suitable for large-scale purification.
    Type: Application
    Filed: December 3, 2013
    Publication date: April 3, 2014
    Applicant: CSL Behring GmbH
    Inventors: Nathan Brinkman, Douglas Bigler, Reinhard Bolli, Vreni Foertsch
  • Patent number: 8653245
    Abstract: This invention relates to protein separation and purification methods for both alpha-1-antitrypsin (AAT, also known as alpha-1 proteinase inhibitor, API, and A.sub.1-PI) and Apolipoprotein A-I (ApoA-1) from, for example, a fraction of human blood plasma. In certain embodiments, the invention provides methods for separating AAT from ApoA-1 at the initial stage of purification, so that the same starting material can be used as a source for both proteins. The methods further pertain to providing compositions of AAT and of ApoA-1 suitable for pharmaceutical use and are suitable for large-scale purification.
    Type: Grant
    Filed: April 5, 2013
    Date of Patent: February 18, 2014
    Assignee: CSL Behring GmbH
    Inventors: Nathan Brinkman, Douglas Bigler, Reinhard Bolli, Vreni Foertsch
  • Publication number: 20130190226
    Abstract: A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as ApoAI or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g/L and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75. The formulation is useful for treating diseases or conditions such as cardiovascular disease, hypercholesterolaemia and hypocholesterolaemia inclusive of acute coronary syndrome (ACS), atherosclerosis and myocardial infarction.
    Type: Application
    Filed: June 30, 2011
    Publication date: July 25, 2013
    Inventors: Samuel Wright, Martin Imboden, Reinhard Bolli, Marcel Waelchli
  • Patent number: 8436152
    Abstract: This invention relates to protein separation and purification methods for both alpha-1-antitrypsin (AAT, also known as alpha-1 proteinase inhibitor, API, and A1-PI) and Apolipoprotein A-I (ApoA-I) from, for example, a fraction of human blood plasma. In certain embodiments, the invention provides methods for separating AAT from ApoA-I at the initial stage of purification, so that the same starting material can be used as a source for both proteins. The methods further pertain to providing compositions of AAT and of ApoA-I suitable for pharmaceutical use and are suitable for large-scale purification.
    Type: Grant
    Filed: August 15, 2008
    Date of Patent: May 7, 2013
    Assignee: CSL Behring GmbH
    Inventors: Nathan Brinkman, Douglas Bigler, Reinhard Bolli, Vreni Foertsch
  • Publication number: 20130102760
    Abstract: The present invention relates to a protein preparation having increased stability, comprising a stabiliser selected from the group consisting of non-polar and basic amino acids and having a pH of 4.0 to 5.2. The invention further relates to a pharmaceutical composition and a method of stabilising protein preparations.
    Type: Application
    Filed: September 14, 2012
    Publication date: April 25, 2013
    Inventors: Reinhard BOLLI, Gerhard Hodler, Regula Styger
  • Publication number: 20110087008
    Abstract: This invention relates to protein separation and purification methods for both alpha-1-antitrypsin (AAT, also known as alpha-1 proteinase inhibitor, API, and A1-PI) and Apolipoprotein A-I (ApoA-1) from, for example, a fraction of human blood plasma. In certain embodiments, the invention provides methods for separating AAT from ApoA-1 at the initial stage of purification, so that the same starting material can be used as a source for both proteins. The methods further pertain to providing compositions of AAT and of ApoA-1 suitable for pharmaceutical use and are suitable for large-scale purification.
    Type: Application
    Filed: August 15, 2008
    Publication date: April 14, 2011
    Inventors: Nathan Brinkman, Douglas Bigler, Reinhard Bolli, Vreni Foertsch
  • Publication number: 20070122402
    Abstract: The present invention relates to a protein preparation having increased stability, comprising a stabiliser selected from the group consisting of non-polar and basic amino acids and having a pH of 4.0 to 5.2. The invention further relates to a pharmaceutical composition and a method of stabilising protein preparations.
    Type: Application
    Filed: November 17, 2004
    Publication date: May 31, 2007
    Inventors: Reinhard Bolli, Gerhard Hodler, Regula Styger